| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Article abstract-Cognitive impairment affects 40 to 70% of patients with multiple sclerosis (MS), but its occurrence cannot be predicted from knowledge of the individual patient's age, level of physical disability, duration of disease, disease type, or performance on standard mental status examinations. To evaluate the usefulness of a brief screening battery, the Screening Examination for Cognitive Impairment (SEFCI), 103 community-dwelling MS patients and 32 healthy normal controls received the SEFCI and a 2-hour battery of other neuropsychological tests chosen for their sensitivity to the cognitive impairments most often observed in MS. Performance on the SEFCI correctly identified 86% of the patients with impairment on any of the 11 measures from the longer battery, 100% of the patients with impairments in at least three cognitive domains, and 90% of the patients without cognitive impairment. Because the SEFCI is sensitive, specific, and easily administered and scored, it should aid the physician in deciding whether to refer an MS patient for a complete evaluation.
NEUROLOGY 1995;45: 718-723
This article has been cited by other articles:
|
|
 |
|
  S Vanotti, R. Benedict, L Acion, F Caceres, and and VANEM Workgroup Validation of the Multiple Sclerosis Neuropsychological Screening Questionnaire in Argentina Multiple Sclerosis, February 1, 2009; 15(2): 244 - 250. [Abstract] [PDF]
|
|
|
|
|
|
A.P. Turner, D.R. Kivlahan, A.P. Sloan, and J.K. Haselkorn Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model Multiple Sclerosis, November 1, 2007; 13(9): 1146 - 1152. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Dutta and B. D. Trapp Pathogenesis of axonal and neuronal damage in multiple sclerosis Neurology, May 29, 2007; 68(22_suppl_3): S22 - S31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Khan Can clinical outcomes be used to detect neuroprotection in multiple sclerosis? Neurology, May 29, 2007; 68(22_suppl_3): S64 - S71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Scherer, I.K. Penner, A. Rohr, H. Boldt, I. Ringel, H. Wilke-Burger, E. Burger-Deinerth, K. Isakowitsch, M. Zimmermann, S. Zahrnt, et al. The Faces Symbol Test, a newly developed screening instrument to assess cognitive decline related to multiple sclerosis: first results of the Berlin Multi-Centre FST Validation Study Multiple Sclerosis, April 1, 2007; 13(3): 402 - 411. [Abstract] [PDF]
|
|
|
|
|
|
B A Parmenter, B Weinstock-Guttman, N Garg, F Munschauer, and R H. Benedict Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test Multiple Sclerosis, January 1, 2007; 13(1): 52 - 57. [Abstract] [PDF]
|
|
|
|
|
|
R F Brown, C C Tennant, M Sharrock, S Hodgkinson, S M Dunn, and J D Pollard Relationship between stress and relapse in multiple sclerosis: part I. Important features Multiple Sclerosis, August 1, 2006; 12(4): 453 - 464. [Abstract] [PDF]
|
|
|
|
|
|
R F Brown, C C Tennant, M Sharrock, S Hodgkinson, S M Dunn, and J D Pollard Relationship between stress and relapse in multiple sclerosis: part II. Direct and indirect relationships Multiple Sclerosis, August 1, 2006; 12(4): 465 - 475. [Abstract] [PDF]
|
|
|
|
|
|
R H. Lazeron, J B Boringa, M Schouten, B M. Uitdehaag, E Bergers, J Lindeboom, M J Eikelenboom, P H Scheltens, F Barkhof, and C H Polman Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis Multiple Sclerosis, October 1, 2005; 11(5): 524 - 531. [Abstract] [PDF]
|
|
|
|
|
|
H Zephir, J de Seze, K Dujardin, G Dubois, M Cabaret, S Bouillaguet, D Ferriby, T Stojkovic, and P Vermersch One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis Multiple Sclerosis, June 1, 2005; 11(3): 360 - 363. [Abstract] [PDF]
|
|
|
|
|
|
R. H. Benedict, D. Cox, L. L Thompson, F. Foley, B. Weinstock-Guttman, and F. Munschauer Reliable screening for neuropsychological impairment in multiple sclerosis Multiple Sclerosis, December 1, 2004; 10(6): 675 - 678. [Abstract] [PDF]
|
|
|
|
|
|
R. H. Lazeron, S. A. Rombouts, P. Scheltens, C. H Polman, and F. Barkhof An fMRI study of planning-related brain activity in patients with moderately advanced multiple sclerosis Multiple Sclerosis, October 1, 2004; 10(5): 549 - 555. [Abstract] [PDF]
|
|
|
|
|
|
R H. Benedict, F Munschauer, R Linn, C Miller, E Murphy, F Foley, and L Jacobs Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire Multiple Sclerosis, February 1, 2003; 9(1): 95 - 101. [Abstract] [PDF]
|
|
|
|
|
|
R L Aupperle, W W Beatty, F deNAP Shelton, and S T Gontkovsky Three screening batteries to detect cognitive impairment in multiple sclerosis Multiple Sclerosis, October 1, 2002; 8(5): 382 - 389. [Abstract] [PDF]
|
|
|
|
|
|
W W Beatty Fluency in multiple sclerosis: which measure is best? Multiple Sclerosis, June 1, 2002; 8(3): 261 - 264. [Abstract] [PDF]
|
|
|
|
|
|
A Solari, L Mancuso, A Motta, L Mendozzi, and C Serrati Comparison of two brief neuropsychological batteries in people with multiple sclerosis Multiple Sclerosis, April 1, 2002; 8(2): 169 - 176. [Abstract] [PDF]
|
|
|
|
 |
|
 R. A. Bermel, R. Bakshi, C. Tjoa, S. R. Puli, and L. Jacobs Bicaudate Ratio as a Magnetic Resonance Imaging Marker of Brain Atrophy in Multiple Sclerosis Arch Neurol, February 1, 2002; 59(2): 275 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. DeSousa, R. H. Albert, and B. Kalman Cognitive impairments in multiple sclerosis: A review American Journal of Alzheimer's Disease and Other Dementias, January 1, 2002; 17(1): 23 - 29. [Abstract] [PDF]
|
|
|
|
|
|
R. Bakshi, S. Ariyaratana, R. H. B. Benedict, and L. Jacobs Fluid-Attenuated Inversion Recovery Magnetic Resonance Imaging Detects Cortical and Juxtacortical Multiple Sclerosis Lesions Arch Neurol, May 1, 2001; 58(5): 742 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Fulton, R. I. Grossman, J. Udupa, L. J. Mannon, M. Grossman, L. Wei, M. Polansky, and D. L. Kolson MR Lesion Load and Cognitive Function in Patients with Relapsing-Remitting Multiple Sclerosis AJNR Am. J. Neuroradiol., November 1, 1999; 20(10): 1951 - 1955. [Abstract] [Full Text]
|
|
|
|
|
|
D. C. Mohr, W. Likosky, P. Dwyer, J. Van Der Wende, A. C. Boudewyn, and D. E. Goodkin Course of Depression During the Initiation of Interferon Beta-1a Treatment for Multiple Sclerosis Arch Neurol, October 1, 1999; 56(10): 1263 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W Beatty Assessment of cognitive and psychological functions in patients with multiple sclerosis: considerations for databasing Multiple Sclerosis, August 1, 1999; 5(4): 239 - 243. [Abstract] [PDF]
|
|
|
|
|
|
R. H Paul, W. W Beatty, R. Schneider, C. Blanco, and K. Hames Impairments of attention in individuals with Multiple Sclerosis Multiple Sclerosis, October 1, 1998; 4(5): 433 - 439. [Abstract] [PDF]
|
|
|
|
|
|
W. W. Beatty Multiple Sclerosis Screening Examinations Arch Neurol, April 1, 1997; 54(4): 352 - 352. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
